ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ARTV vs PLX // OPERATING MARGIN

Artiva Biotherapeutics Inc. (NASDAQ) VS. Protalix BioTherapeutics Inc. (NYSE) • 15-METRIC TALLY: ARTV 1 — PLX 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARTV VS. PLX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ARTV PLX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 48.80% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -13.00% -22.00 PLX /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -6.48% — TIE /fcf-yield <GO>
Operating Margin ACTIVE — -10.40% — TIE /operating-margins <GO>
Net Profit Margin — -12.50% — TIE /net-margins <GO>
Revenue Growth (YoY) — -1.20% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 1.03 0.20 +0.83 ARTV /balance-sheet <GO>
Piotroski F-Score Quality 2/9 2/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 20.6 47.3 -26.66 PLX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $206.8M $210.3M -$3.5M PLX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ARTV REV PLX REV ARTV GROSS % PLX GROSS % ARTV FCF PLX FCF
FY 2025 $0 $52.7M — 48.8% -$79.3M -$13.6M
FY 2024 $251.0K $53.4M — 54.5% -$55.7M $7.4M
FY 2023 $32.9M $65.5M — — -$47.4M -$1.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARTV // BETA —
PLX // BETA —